Evotec SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
January 19, 2021 at 04:40 am EST
Share
DGAP Preliminary announcement financial reports: Evotec SE
/ Preliminary announcement on the disclosure of financial statements
Evotec SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
19.01.2021 / 10:39
Preliminary announcement of the publication of quarterly reports and quarterly/interim statements transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Evotec SE hereby announces that the following financial reports shall be disclosed:
Report Type: Quarterly/ Interim statement within the 1st half-year
Language: German
Date of disclosure: May 11, 2021
Address: https://www.evotec.com/de/invest/finanzpublikationen
Language: English
Date of disclosure: May 11, 2021
Address: https://www.evotec.com/en/invest/financial-publications
Report Type: Quarterly/ Interim statement within the 2nd half-year
Language: German
Date of disclosure: November 11, 2021
Address: https://www.evotec.com/de/invest/finanzpublikationen
Language: English
Date of disclosure: November 11, 2021
Address: https://www.evotec.com/en/invest/financial-publications
19.01.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women's health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
EVOTEC SE 
